 Robert Lyle
Concepts (161)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 7 | 2025 | 583 | 1.090 |
Why?
| | Fetal Blood | 4 | 2025 | 79 | 0.940 |
Why?
| | Blood Cells | 3 | 2017 | 37 | 0.630 |
Why?
| | Flow Cytometry | 1 | 2016 | 397 | 0.450 |
Why?
| | Epigenesis, Genetic | 4 | 2025 | 401 | 0.400 |
Why?
| | Ductus Arteriosus, Patent | 2 | 2019 | 40 | 0.290 |
Why?
| | Infant, Newborn | 9 | 2023 | 2859 | 0.270 |
Why?
| | DNA | 1 | 2010 | 543 | 0.260 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 146 | 0.240 |
Why?
| | Asthma | 1 | 2010 | 314 | 0.240 |
Why?
| | Leukocytes | 1 | 2025 | 59 | 0.220 |
Why?
| | Infant, Premature | 4 | 2019 | 327 | 0.200 |
Why?
| | Endometrial Neoplasms | 1 | 2024 | 143 | 0.200 |
Why?
| | Female | 18 | 2025 | 28055 | 0.190 |
Why?
| | Medicaid | 2 | 2018 | 263 | 0.190 |
Why?
| | Disabled Children | 2 | 2013 | 62 | 0.180 |
Why?
| | Pregnancy | 5 | 2023 | 2658 | 0.170 |
Why?
| | Humans | 24 | 2025 | 52114 | 0.170 |
Why?
| | Life Style | 1 | 2021 | 146 | 0.170 |
Why?
| | Epigenomics | 1 | 2020 | 74 | 0.160 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 9 | 0.160 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 183 | 0.160 |
Why?
| | Child | 10 | 2023 | 7147 | 0.160 |
Why?
| | Hospitalization | 2 | 2017 | 739 | 0.150 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2019 | 12 | 0.150 |
Why?
| | Databases, Genetic | 1 | 2019 | 82 | 0.150 |
Why?
| | Chronic Disease | 3 | 2011 | 585 | 0.150 |
Why?
| | Adult | 9 | 2025 | 14095 | 0.150 |
Why?
| | Health Care Costs | 2 | 2018 | 174 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 174 | 0.140 |
Why?
| | Male | 12 | 2025 | 26652 | 0.140 |
Why?
| | Child, Preschool | 7 | 2018 | 4001 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 77 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2021 | 2282 | 0.140 |
Why?
| | Computational Biology | 1 | 2019 | 209 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 292 | 0.140 |
Why?
| | Case-Control Studies | 4 | 2024 | 1193 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2018 | 53 | 0.130 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2017 | 29 | 0.130 |
Why?
| | Gene Library | 1 | 2016 | 42 | 0.130 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 48 | 0.130 |
Why?
| | Reference Standards | 1 | 2016 | 51 | 0.130 |
Why?
| | Cohort Studies | 5 | 2023 | 1541 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2017 | 106 | 0.130 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2016 | 17 | 0.130 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 17 | 0.120 |
Why?
| | Anesthesia, Epidural | 1 | 2016 | 26 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2016 | 60 | 0.120 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 97 | 0.120 |
Why?
| | Pre-Eclampsia | 1 | 2016 | 58 | 0.120 |
Why?
| | Diabetes, Gestational | 1 | 2016 | 52 | 0.120 |
Why?
| | DNA Copy Number Variations | 2 | 2016 | 117 | 0.120 |
Why?
| | Developmental Disabilities | 1 | 2016 | 121 | 0.120 |
Why?
| | Placenta | 1 | 2016 | 152 | 0.110 |
Why?
| | Hospitals, Pediatric | 3 | 2013 | 239 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 515 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2020 | 624 | 0.100 |
Why?
| | Comprehensive Health Care | 1 | 2013 | 9 | 0.100 |
Why?
| | Time Factors | 3 | 2020 | 2970 | 0.100 |
Why?
| | Norway | 2 | 2024 | 5 | 0.100 |
Why?
| | Infant | 6 | 2018 | 3660 | 0.100 |
Why?
| | Middle Aged | 7 | 2024 | 13028 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 1000 | 0.090 |
Why?
| | Genome, Human | 1 | 2012 | 121 | 0.090 |
Why?
| | Child, Exceptional | 1 | 2011 | 5 | 0.090 |
Why?
| | Aged | 6 | 2024 | 10142 | 0.090 |
Why?
| | Cost Savings | 1 | 2011 | 58 | 0.080 |
Why?
| | Prospective Studies | 2 | 2021 | 2424 | 0.080 |
Why?
| | Parents | 1 | 2013 | 334 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2010 | 147 | 0.080 |
Why?
| | Young Adult | 4 | 2025 | 4307 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2010 | 123 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2018 | 742 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 503 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2011 | 239 | 0.080 |
Why?
| | Phosphoproteins | 2 | 2017 | 120 | 0.080 |
Why?
| | Patient Care Team | 1 | 2011 | 271 | 0.070 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 34 | 0.070 |
Why?
| | CpG Islands | 2 | 2020 | 114 | 0.070 |
Why?
| | Genotype | 1 | 2010 | 563 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2024 | 853 | 0.070 |
Why?
| | Child Health Services | 1 | 2009 | 78 | 0.070 |
Why?
| | Home Care Services | 1 | 2009 | 71 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 504 | 0.070 |
Why?
| | Incidence | 2 | 2021 | 1070 | 0.060 |
Why?
| | Adolescent | 4 | 2020 | 6681 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2020 | 3382 | 0.060 |
Why?
| | Patient Discharge | 2 | 2018 | 322 | 0.060 |
Why?
| | Genomics | 2 | 2016 | 265 | 0.060 |
Why?
| | Australia | 1 | 2023 | 90 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 670 | 0.050 |
Why?
| | Embryonic Stem Cells | 1 | 2022 | 19 | 0.050 |
Why?
| | Age Factors | 2 | 2018 | 1125 | 0.050 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 184 | 0.050 |
Why?
| | Occult Blood | 1 | 2021 | 23 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2002 | 103 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 2002 | 63 | 0.040 |
Why?
| | Arkansas | 3 | 2013 | 2016 | 0.040 |
Why?
| | Adipocytes | 1 | 2002 | 130 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2002 | 138 | 0.040 |
Why?
| | Colonoscopy | 1 | 2021 | 107 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 250 | 0.040 |
Why?
| | Cell Survival | 1 | 2022 | 596 | 0.040 |
Why?
| | MicroRNAs | 1 | 2024 | 385 | 0.040 |
Why?
| | Blood Banks | 1 | 2020 | 18 | 0.040 |
Why?
| | Neurons | 1 | 2022 | 391 | 0.040 |
Why?
| | Proteins | 1 | 2002 | 347 | 0.040 |
Why?
| | Time | 1 | 2018 | 29 | 0.040 |
Why?
| | Ibuprofen | 1 | 2018 | 24 | 0.040 |
Why?
| | Indomethacin | 1 | 2018 | 36 | 0.040 |
Why?
| | United States | 3 | 2018 | 5168 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 111 | 0.040 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2018 | 39 | 0.040 |
Why?
| | Birth Weight | 1 | 2019 | 128 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 166 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 418 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2017 | 69 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 108 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 106 | 0.030 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2017 | 67 | 0.030 |
Why?
| | Glycoproteins | 1 | 2017 | 122 | 0.030 |
Why?
| | Genome | 1 | 2016 | 60 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2017 | 198 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2016 | 149 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2017 | 150 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 2093 | 0.030 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 57 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 219 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 243 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 663 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 925 | 0.030 |
Why?
| | Bone Density | 1 | 2017 | 394 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 714 | 0.030 |
Why?
| | Length of Stay | 1 | 2018 | 666 | 0.030 |
Why?
| | Blood Glucose | 1 | 2016 | 475 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1339 | 0.030 |
Why?
| | Bone and Bones | 1 | 2017 | 492 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2016 | 1214 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 176 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 2012 | 16 | 0.020 |
Why?
| | Individuality | 1 | 2012 | 29 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2013 | 139 | 0.020 |
Why?
| | Myelodysplastic Syndromes | 1 | 2012 | 85 | 0.020 |
Why?
| | Cerebral Palsy | 1 | 2010 | 37 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 267 | 0.020 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2010 | 63 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 600 | 0.020 |
Why?
| | Quality of Life | 1 | 2013 | 878 | 0.020 |
Why?
| | Program Evaluation | 1 | 2009 | 350 | 0.020 |
Why?
| | Rural Population | 1 | 2011 | 571 | 0.020 |
Why?
| | Mutation | 1 | 2012 | 1318 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2018 | 6610 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 5456 | 0.010 |
Why?
| | Leupeptins | 1 | 2002 | 6 | 0.010 |
Why?
| | Retinoblastoma-Like Protein p130 | 1 | 2002 | 8 | 0.010 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2002 | 21 | 0.010 |
Why?
| | Calpain | 1 | 2002 | 25 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 616 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2002 | 246 | 0.010 |
Why?
| | Cell Line | 1 | 2002 | 1018 | 0.010 |
Why?
| | Animals | 1 | 2002 | 13332 | 0.000 |
Why?
|
|
Lyle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|